Antibody in asthma treatment:
**Core Concept**
The question is testing the concept of using antibodies as a treatment for asthma. This involves understanding the role of immunoglobulins in modulating the immune response and their potential therapeutic applications in respiratory diseases like asthma.
**Why the Correct Answer is Right**
Omalizumab, a recombinant humanized monoclonal antibody, is used in the treatment of severe persistent asthma. It targets the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby reducing IgE-mediated allergic responses. By binding to IgE, omalizumab prevents IgE from binding to its receptor, leading to a decrease in mast cell activation and subsequent reduction in airway inflammation and symptoms. This mechanism is particularly useful in patients with severe asthma who are unresponsive to conventional treatments.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not specify an antibody treatment for asthma. While corticosteroids are commonly used in asthma treatment, they are not antibodies.
**Option B:** This option is incorrect because it refers to a medication used in the treatment of attention deficit hyperactivity disorder (ADHD), not asthma. Methylphenidate is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the brain.
**Option C:** This option is incorrect because it refers to a medication used in the treatment of hypertension and heart failure, not asthma. Losartan is an angiotensin II receptor antagonist that blocks the effects of angiotensin II on blood vessels.
**Clinical Pearl / High-Yield Fact**
Omalizumab is a biologic agent that requires regular monitoring of IgE levels and eosinophil counts to assess its effectiveness and minimize the risk of anaphylaxis.
**Correct Answer:** Omalizumab.